儿童多系统炎症综合征（MIS-C）是一种类川崎病样表现的严重炎症综合征，可表现出中毒性休克和心源性 或血管麻痹性休克。MIS-C具有不典型的发病年龄（年龄偏大）和种族背景（非亚裔）。MIS-C病情危重，可短时间内快速进 展并恶化。由于存在严重急性呼吸综合征冠状病毒2（SARS-CoV- 2）感染的证据（RT-PCR或者血清学检测），MIS-C的发 生与SARS-CoV- 2有潜在联系。MIS-C的发病机制尚不清楚，目前主要沿用川崎病或新型冠状病毒肺炎（COVID- 19）的治 疗策略，一些新的治疗方案也不断出现。文章综述MIS-C诊疗相关研究现状与进展。

Multisystem inflammatory syndrome in children (MIS-C) is a severe inflammatory syndrome diagnosed as Kawasaki-like disease manifested by toxic shock and cardiogenic or vascular paralytic shock. MIS-C usually has atypical onset age (older) and ethnic background (non-Asian). MIS-C is a severe condition and can progress rapidly and deteriorate in a short time. MIS-C is potentially associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV- 2 ). Since the pathogenesis of MIS-C is unclear, the treatments of MIS-C are based on treatment strategies in Kawasaki disease or coronavirus disease 2019 (COVID- 19 ), and it is reported some of new treatment strategies are effective. This article reviews the status and progress of diagnosis and treatment for MIS-C.